Name: Ethosuximide
Brand: Selleck Chemicals
SKU: S4626
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: Purity: 99.84%

99.84

Related Targets	CFTR CRM1 CD markers AChR Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR
Other Calcium Channel Inhibitors	Bay K 8644 BAPTA-AM Tetrandrine Flunarizine 2HCl Nilvadipine Cilnidipine YM-58483 (BTP2) Ionomycin Imperatorin Manidipine 2HCl

Solubility

In vitro
Batch:

DMSO : 28 mg/mL (198.34 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 28 mg/mL

Ethanol : 28 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	141.17	Formula	C₇H₁₁NO₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	77-67-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Zarontin			SMILES	CCC1(CC(=O)NC1=O)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro	Ethosuximide(ETH) enhances hippocampal derived NSC proliferation and neurospheres formation in vitro. Low concentration of ETH induces proliferation of NSC, while higher concentrations of ETH are cytotoxic. Also, ETH activates the PI3K/Akt signal transduction pathway in adult hippocampal NSC in vitro. Blockade of the PI3K/Akt pathway inhibits ETH induced hippocampal NSC neuronal differentiation.
In vivo	Anti-epileptic drug ethosuximide rescues the short lifespan and chemosensory defects exhibited by C. elegans null mutants of dnj-14, the worm orthologue of the DNAJC5 gene mutated in autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. It also ameliorates the locomotion impairment and short lifespan of worms expressing a human Tau mutant that causes frontotemporal dementia. Ethosuximide extends lifespan by inhibiting the function of specific chemosensory neurons. It increases neurogenesis, reduces neurodegeneration, and reverses cognitive impairments in rat model of AD like phenotypes.
References	[1] https://pubmed.ncbi.nlm.nih.gov/26419537/ [2] https://pubmed.ncbi.nlm.nih.gov/18949032/ [3] https://pubmed.ncbi.nlm.nih.gov/26420483/ [4] https://pubmed.ncbi.nlm.nih.gov/2545161/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2020-01-03)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04217733	RECRUITING	IBS - Irritable Bowel Syndrome	Tanta University	2019-11-01	PHASE3
NCT04431778	UNKNOWN	Peripheral Neuropathic Pain	University Hospital, Clermont-Ferrand	2020-11-01	PHASE2
NCT02973542	COMPLETED	Irritable Bowel Syndrome	University Hospital, Clermont-Ferrand	2018-02-08	PHASE2
NCT03887624	COMPLETED	Depressive Disorder, Treatment-Resistant	Zhejiang University	2019-05-21	EARLY_PHASE1
NCT02973542	Unknown status	Irritable Bowel Syndrome	University Hospital Clermont-Ferrand\|SFETD (Socièté Française d''Etude et de Traitement de la Douleur)	2018-04-30	Phase 2
NCT02100046	COMPLETED	Neuropathic Traumatic Pain; Pain NRS ≥ 4; Peripheral Neuropathic Pain; Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4	University Hospital, Clermont-Ferrand	2014-03	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Ethosuximide Calcium Channel inhibitor

Chemical Structure

Molecular Weight: 141.17